The findings support the use of ezetimibe as an effective monotherapy for reducing Lp(a) levels in patients with primary hypercholesterolemia. This has implications for managing patients with elevated Lp(a) who are at higher cardiovascular risk. The gene discussed is LPA; the disease is familial hypercholesterolemia.